SCHEMBL2458151

SCHEMBL2458151

N[N+]12C=CN=CC1=C(C1CC(CNCCO)C1)N=C2c1cccc(OCc2ccccc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 6/20 0.38
TNK2 Q07912 1/20 0.38
BCHE P06276 5/20 0.36
SPHK2 Q9NRA0 1/20 0.35
SPHK1 Q9NYA1 1/20 0.35
ABL1 P00519 1/20 0.34
EGFR P00533 1/20 0.34
ABL2 P42684 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
HTR6 P50406 1/20 0.33
ROCK2 O75116 1/20 0.33
PRKD3 O94806 1/20 0.33
INSR P06213 1/20 0.33
LYN P07948 1/20 0.33
RET P07949 1/20 0.33
FGFR1 P11362 1/20 0.33
RPS6KB1 P23443 1/20 0.33
FLT4 P35916 1/20 0.33
FLT3 P36888 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2463565 0.93 IGF1R (0.38) IGF1RTNK2BCHEROCK2PRKD3
SCHEMBL2457346 0.93 IGF1R (0.38) IGF1RTNK2BCHESPHK2SPHK1
SCHEMBL2457528 0.92 IGF1R (0.39) IGF1RTNK2BCHESPHK2SPHK1
SCHEMBL2461856 0.92 IGF1R (0.39) IGF1RTNK2BCHEHTR6ROCK2
SCHEMBL2459711 0.90 IGF1R (0.41) IGF1RTNK2CYP4F2CYP4A11ROCK2
SCHEMBL2460614 0.90 IGF1R (0.43) IGF1RTNK2SPHK2PDCD1CD274
SCHEMBL2460659 0.89 IGF1R (0.47) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2460490 0.89 IGF1R (0.39) IGF1RTNK2ROCK2PRKD3INSR
SCHEMBL2459434 0.88 HTR6 (0.40) IGF1RTNK2BCHECYP4F2CYP4A11
SCHEMBL2463514 0.87 IGF1R (0.50) IGF1RTNK2ROCK2PRKD3INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP claimed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US claimed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US claimed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US claimed
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885BCHE 4603/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885BCHE 4603/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 IGF1R 1/4885TNK2 760/4885BCHE 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.